Up 23% this year, why Ramsay Health Care shares are tipped for more 'compelling upside'

A leading fund manager forecasts more outperformance from Ramsay Health Care's rebounding share price.

Ramsay Health Care Ltd (ASX: RHC) shares are edging lower today.

Shares in the S&P/ASX 200 Index (ASX: XJO) healthcare stock closed yesterday trading for $42.74. In late morning trade on Friday, shares are changing hands for $42.65 apiece, down 0.2%.

For some context, the ASX 200 is just about flat at this same time.

Taking a step back, Ramsay Health Care shares have strongly outperformed in 2026, up 23.3% compared to the 0.3% year-to-date gains posted by the benchmark index.

And the ASX 200 healthcare stock also recently increased its passive income payouts, boosting its fully-franked interim dividend by 6.3% to 42.5 cents a share.

Ramsay Health Care stock currently trades on a 1.9% fully-franked trailing dividend yield.

And looking ahead, Nathan Hughes, an Australian equities portfolio manager at Perpetual Ltd (ASX: PPT), believes there's plenty more upside potential for the Aussie-focused healthcare provider (courtesy of the Australian Financial Review).

Here's why.

Two women look happily at an X-ray of a person's chest with one giving the thumbs up sign.

Image source: Getty Images

Should I buy Ramsay Health Care shares today?

Asked which stock his fund holds that's most undervalued by the market, Hughes replied, "Ramsay Health Care presents compelling upside."

He noted, "The negatives, such as labour inflation and changes to private health insurance rebates that may impact industry participation, are now well understood."

And Ramsay Health Care shares could benefit from their renewed focus on the Aussie market.

According to Hughes:

Beyond the demerger of the Ramsay Santé assets – the European hospitals business Ramsay announced it would spin off in February – we think it's clear the focus of the company is the core Australian business.

There is significant opportunity to improve operating performance and asset productivity in this division, with a sensible approach to capacity and utilisation in contrast to years of expansion. As such, return on invested capital should improve.

Hughes also pointed to the company's strong balance sheet and the fully-franked dividend on offer as reasons to be optimistic for ongoing share price growth.

He concluded:

Further capital repatriation from offshore is not out of the question in the medium term. This would give the company plenty of financial flexibility, noting Ramsay has a large balance of surplus franking credits.

What's the latest from the ASX 200 healthcare stock?

Ramsay reported its half-year results (H1 FY 2026) on 26 February.

Highlights for the six months to 31 December included underlying earnings before interest and tax (EBIT) of $536.7 million, up 7.3% year on year.

And on the bottom line, underlying net profit after tax (NPAT) of $171.7 million increased by 8.1%.

Ramsay Health Care shares closed up 10.4% on the day of the results release.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »